UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/910,354	07/20/2001	Kevin A. Jarrell	2003320-0032	2372	
	7590 10/30/200 LL & STEWART LLP		EXAMINER		
	ATIONAL PLACE		VOGEL, NANCY TREPTOW		
bos ion, ma	02110		ART UNIT	PAPER NUMBER	
			1636		
			NOTIFICATION DATE	DELIVERY MODE	
			10/30/2008	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@choate.com

Office Action Summary		Application No. Applicant(s)							
		09/910,354		JARRELL ET AL.					
			Examiner		Art Unit				
			NANCY VO	GEL	1636				
 Period for	The MAILING DATE of this commun	ication appe	ears on the o	cover sheet with the c	orrespondence ad	ldress			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).									
Status									
1) ∑ F	Responsive to communication(s) file	ed on <i>08 Auc</i>	aust 2008						
•	Responsive to communication(s) filed on <u>08 August 2008</u> . This action is FINAL . 2b)⊠ This action is non-final.								
/ —		<i>7</i> —			secution as to the	e merits is			
<i>,</i> —	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
	n of Claims		. ,	,,					
·			411:	Li					
•	Claim(s) <u>1,2,4,5,12 and 14-21</u> is/are pending in the application.								
	4a) Of the above claim(s) is/are withdrawn from consideration.								
·	5) Claim(s) is/are allowed.								
·	Claim(s)	e rejectea.							
•	Claim(s) is/are objected to.								
8)[] (Claim(s) are subject to restric	ction and/or	election rec	luirement.					
Applicatio	n Papers								
9)□ ⊤	he specification is objected to by th	e Examiner.							
10) <u></u> ⊤	he drawing(s) filed on is/are:	: a) <u>□</u> acce _l	pted or b)⊑	objected to by the B	Examiner.				
A	applicant may not request that any obje	ction to the di	rawing(s) be	held in abeyance. See	e 37 CFR 1.85(a).				
F	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority ur	der 35 U.S.C. § 119								
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 									
2) Notice 3) Informa	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (Fation Disclosure Statement(s) (PTO/SB/08) No(s)/Mail Date 4/15/08, 2/11/08.	PTO-948)		Interview Summary Paper No(s)/Mail Da Notice of Informal P Other:	ite				

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 8/8/08 has been entered.

Claims 1, 2, 4, 5, 12, 14-21 are pending in the case.

Receipt of the Information Disclosure Statements on 4/15/08 and 2/11/08 is acknowledged.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1, 2, 4, 5, 12, 14-21 are rejected under 35 U.S.C. 102(e) as being anticipated by Harney et al. (US Patent 6,495,318).

Harney disclose a method of preparing a DNA vector, comprising providing at least two collections of nucleic acid molecules that are DNA vector fragments, wherein each of the collections comprises alternative vector fragments to be included in the vector, wherein vector fragments within the first collection each comprise at least a first portion of a first vector element and a first portion of a second vector element (a first portion of an antibiotic resistance marker encoding gene, for instance) which first portion of the second vector element cannot alone provide a second vector element function (the function of antibiotic resistance); and vector fragments within the second collection each comprise a second portion of the second vector element (a second part of an antibiotic resistance encoding gene for instance), which second portion of the second vector element also cannot alone provide the second vector element function, the first and second portions of the second vector element being selected and the vector fragments being designed such that when a vector fragment from the first collection is ligated with a vector fragment from the second collection the second vector element function is reconstituted, and mixing at least one vector fragment from each collection with one another under linkage conditions so that a hybrid molecule in which each of the fragments is linked together is produced. See Figure Fig. 1 and col. 1, lines 58-col. 2, line 15, and see col. 17, lines 15-23). The reference discloses that the selected nucleic acid molecules contain at least one overhang that is complementary with an overhang on at least one of the other selected molecules (col. 2, lines 33-41). The reference discloses the further introduction of the hybrid molecule (ie vector) into a cell (see col. 56, lines 18-23). The reference discloses that each nucleic molecule in each of said

Art Unit: 1636

collections contains at least a portion of a vector element such as a promoter, selectable marker, replication origin, transcription terminator, etc. (Fig. 1 and column 7, lines 11-26). The reference discloses admixing under ligase conditions (see col. 17, lines 61-65). The vector fragments contain selectable or detectable genetic units (see Fig. 1). The reference discloses said method wherein the step of admixing further comprises admixing an isolated nucleic acid molecule containing insert sequence (ie the gene of interest in Fig. 1). The first vector element provides a first vector element function, such as a promoter (Fig. 1). The reference discloses that a marker gene may be split between two of the components, which is reconstituted upon ligation of the two components (col. 17 lines 15-23). The first vector element may also be considered to be the half restriction enzyme site present at the left of the fragments shown in Fig. 1, and thus they alone cannot provide a first vector element function i.e. a complete restriction site. The first portion of the first vector element may alternatively be considered the promoter present on the first element shown in Fig. 1. It is noted that the specification defines a vector "element" as "a region of nucleic acid sequence that imparts a particular functional or structural characteristic upon the molecule" (page 8 of the specification). Furthermore, each of the fragments in Fig. 1 may be considered to comprise a first or second portion of a second vector element, which if nucleic acid is inserted between said first and second portion, would prevent creation of the "second vector detection element"; a vector detection element may be a particular pattern of nucleic acid fragments produced upon restriction, and an insertion of nucleic acids between two portions of the "second vector detection element" would not create said

Art Unit: 1636

"second vector detection element". Furthermore, a selectable marker gene which is split between two components or fragments, would fail to function if interrupted by a DNA fragment inserted between the two components or fragments. Therefore, the claims are anticipated.

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NANCY VOGEL whose telephone number is (571)272-0780. The examiner can normally be reached on 7:00 - 3:30, Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached on (571) 272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Application/Control Number: 09/910,354 Page 6

Art Unit: 1636

/NANCY VOGEL/ Primary Examiner, Art Unit 1636

NV 10/25/08